序号 |
|
主题 |
跟贴/点击 |
作者 |
最后回复 |
提示 |
● 药厂相关职位内推-汇总(JNJ, Takeda, Pfizer, GSK) (486b)
|
-- | tlexander 2021-08-27 | -- |
提示 |
● 国内Biotech/Pharma开在美国的分部 (309b)
|
-- | benbenx 2021-06-29 | -- |
3 |
@ |
● ENPP3/CD3双抗: 透明肾细胞癌 (140b)
|
0/36 | tlexander 2022-07-03 | -- |
4 |
|
● 自主独立临床能力需要哪些团队,minimum的team set (47b)
|
0/33 | tlexander 2022-07-03 | -- |
5 |
|
● TAZVERIK作为EZH2的inhibitor销售为什么如此惨不忍睹 (290b)
|
1/118 | tlexander 2022-07-02 | tlexander 07-02 23:30 |
6 |
|
● 报一下队友的第一份业界的Offer (577b)
|
13/2075 | MJ1992 2022-06-28 | EOS 07-02 15:31 |
7 |
|
● 求技术员或研究员的工作 (227b)
|
2/201 | xiaoxizi 2022-07-01 | kc2013 07-01 16:07 |
8 |
|
● Big pharma,biotech PhD以上级别 (406b)
|
10/3293 | Thymine 2022-01-11 | kc2013 07-01 13:02 |
9 |
|
● 国内大药企(民企)怎么样? (87b)
|
0/88 | njmayun 2022-07-01 | -- |
10 |
|
● PI3K这个inhibitor是不是要彻底凉了?? (100b)
|
0/79 | tlexander 2022-06-30 | -- |
11 |
|
● 药厂里面的Computational Chemistry vs Computationa (78b)
|
0/84 | tlexander 2022-06-28 | -- |
12 |
|
● 现在是跳槽去biotech的好时机么 (169b)
|
21/864 | bostonggg 2022-06-21 | EOS 06-27 08:04 |
13 |
|
● 诺华的principle scientist (197b)
|
2/370 | EOS 2022-06-26 | EOS 06-27 07:57 |
14 |
|
● 12个ADC获批,以及超过100个ADC处于临床开发阶段 (2.3k)
|
0/208 | tlexander 2022-06-26 | -- |
15 |
|
● 有 biopharma/biotech/pharma 的微信群吗?? (22b)
|
8/853 | aqqq 2021-12-24 | tlexander 06-26 20:01 |
16 |
|
● bispecific的想象空间如何? (167b)
|
0/87 | tlexander 2022-06-26 | -- |
17 |
|
● Gilead的Yescarta vs BMS的Breyanzi (239b)
|
1/540 | tlexander 2022-06-26 | Tevez10 06-26 17:41 |
18 |
|
● 波士顿药厂形势如何? (137b)
|
10/968 | EOS 2022-06-15 | ducan21 06-26 09:20 |
19 |
|
● 药厂non-compete格式合同,怎么对付? (311b)
|
5/620 | kingsmen 2022-06-21 | ducan21 06-26 09:15 |
20 |
|
● bermekimab的IL-1α inhibitor针对特应性皮炎 (80b)
|
0/36 | tlexander 2022-06-25 | -- |
21 |
|
● 国内Biotech/Pharma开在美国的分部 (309b)
|
16/4713 | benbenx 2021-06-29 | otis 06-20 15:30 |
22 |
|
● 药厂做clinical相关的还是转cs (528b)
|
1/276 | IrisHer 2022-06-16 | yaji 06-19 14:15 |
23 |
|
● 同感找第一份工业界的工作不容易 (363b)
|
15/2313 | ddbl 2022-06-14 | tlexander 06-19 13:21 |
24 |
|
● Genetics和Genomics主要的几个big pharma的对等机构 (262b)
|
0/114 | tlexander 2022-06-19 | -- |
25 |
|
● Johnson & Johnsonn长期职位内推 (556b)
|
15/1603 | tlexander 2022-05-15 | Yupu95 06-18 22:14 |
26 |
|
● 怎么又被一堆十万个为什么给刷屏了 (68b)
|
0/110 | yaji 2022-06-18 | -- |
27 |
|
● 群里做hit-finding,可以关注一下CACHE项目 (321b)
|
0/63 | tlexander 2022-06-18 | -- |
28 |
|
● Multiple Myeloma的market很大吗?为什么这么多药厂 (77b)
|
0/102 | tlexander 2022-06-18 | -- |
29 |
|
● R package for real-word evidence analysis,真实世 (62b)
|
1/113 | tlexander 2022-06-18 | tlexander 06-18 21:08 |
30 |
|
● Astrazeneca有中国人的wechat群吗? (34b)
|
0/98 | tlexander 2022-06-18 | -- |
31 |
|
● 肺癌患者 Osimertinib 奥希替尼耐药后一般该怎么办? (50b)
|
1/46 | tlexander 2022-06-18 | tlexander 06-18 20:43 |
32 |
|
● 肺癌患者如何确定是否发生了对侧淋巴灶转移?? (45b)
|
1/27 | tlexander 2022-06-18 | tlexander 06-18 20:13 |
33 |
|
● protein engineering在大药厂一般处于食物链的哪个环 (133b)
|
0/64 | tlexander 2022-06-18 | -- |
34 |
|
● 肺癌治疗基本原则?开刀 -> 靶向 -> PD1/PDL1 (113b)
|
4/59 | tlexander 2022-06-18 | tlexander 06-18 20:09 |
35 |
|
● PD1,PDL1,对身体素质要求很高啊? (89b)
|
0/51 | tlexander 2022-06-18 | -- |
36 |
|
● 肺癌患者,EGFR和TP53双突变。问题: 手术 vs PD-1 v (85b)
|
2/38 | tlexander 2022-06-18 | tlexander 06-18 19:57 |
37 |
|
● 靶向药物一般10-18个月耐药,为何一定要耐药?机制是 (62b)
|
0/40 | tlexander 2022-06-18 | -- |
38 |
|
● mantle cell lymphoma (MCL)的market竞争激烈吗? (54b)
|
0/27 | tlexander 2022-06-18 | -- |
39 |
|
● Cetrelimab, a PD-1 Inhibitor 联合BALVERSA FGFR in (334b)
|
0/61 | tlexander 2022-06-18 | -- |
40 |
|
● 合成对照臂(synthetic control arm)现在大范围应用 (56b)
|
0/32 | tlexander 2022-06-18 | -- |
41 |
|
● Hiring bioinformatics engineer (99b)
|
1/96 | dfdong 2022-06-15 | tlexander 06-18 15:06 |
42 |
|
● 这条路走的如何:英国NHS(National Health Service, (110b)
|
0/30 | tlexander 2022-06-18 | -- |
43 |
|
● SF旁边的Newark出了一个新公司 Ultima Genomics最近 (55b)
|
1/178 | tlexander 2022-05-31 | melodywong78 06-18 02:38 |
44 |
|
● 可怜的先灵葆雅(Schering)捡到宝贝竟然丢了.. (1.1k)
|
4/811 | tlexander 2022-06-12 | tlexander 06-17 20:38 |
45 |
|
● 为什么不批量化地把人体所有酶的inhibitor一次性都开 (95b)
|
0/52 | tlexander 2022-06-17 | -- |
46 |
|
● 求比较东部药企offer(第一份工作) (740b)
|
8/1803 | focusidea2 2022-06-08 | IrisHer 06-16 21:42 |
47 |
|
● 寻找感兴趣靶点的agonist比antagonist更困难吗? (46b)
|
3/116 | tlexander 2022-06-12 | tlexander 06-14 21:53 |
48 |
|
● 针对趋化因子/趋化因子受体的药物开发怎么这么难?好 (64b)
|
2/88 | tlexander 2022-06-12 | tlexander 06-13 07:23 |
49 |
|
● Regeneron买了Checkmate获得了Vidutolimod (CMP-001) (767b)
|
1/271 | tlexander 2022-06-12 | tlexander 06-12 23:36 |
50 |
|
● Parkinson’s Disease 新药物开发进展 (166b)
|
1/109 | tlexander 2022-06-12 | tlexander 06-12 20:27 |
51 |
|
● Top25 pharma里面管线竞争度比较大的有哪几家? (45b)
|
0/206 | tlexander 2022-06-12 | -- |
52 |
|
● Abbvie的帕金森的药有特效吗?刚交了NDA, 非常期待 (48b)
|
2/166 | tlexander 2022-06-10 | fire110 06-12 13:41 |
53 |
|
● Novavax疫苗稍有增加的心肌炎及中风风险,可以理解吗 (77b)
|
1/71 | tlexander 2022-06-11 | kc2013 06-11 11:12 |
54 |
|
● Big pharma的Scientific Advisory Board的工资一般给 (56b)
|
1/251 | tlexander 2022-06-11 | kc2013 06-11 11:03 |
55 |
|
● 有些人在很多药厂的Scientific Advisory Board里面? (76b)
|
0/127 | tlexander 2022-06-11 | -- |
56 |
|
● 查看岗位薪水区间,哪些网站? (113b)
|
2/360 | fire110 2022-06-08 | Thymine 06-11 10:18 |
57 |
|
● 事实证明Alex Zhavoronkov的策略比Daphne Koller的更 (68b)
|
0/85 | tlexander 2022-06-11 | -- |
58 |
|
● 感觉vision方面GSK和Roche稍微跟强一些? (40b)
|
0/96 | tlexander 2022-06-11 | -- |
59 |
|
● high content cellular phenotype data是Daphne从201 (587b)
|
0/59 | tlexander 2022-06-10 | -- |
60 |
|
● PD1/PDL1能否拿下所有的cancer?好像现在还在一个一 (55b)
|
0/83 | tlexander 2022-06-10 | -- |
61 |
|
● keynote做stunning and memorable presentations (31b)
|
0/34 | tlexander 2022-06-10 | -- |
62 |
|
● Science朱刊发文说FDA advisers greenlight Novavax (157b)
|
1/50 | tlexander 2022-06-10 | tlexander 06-10 20:47 |
63 |
|
● CAR-T估计等通用型获批后,会大踏步前进 (146b)
|
2/122 | tlexander 2022-06-10 | Tevez10 06-10 20:46 |
64 |
|
● Bay Area的insitro,多少人知道? (32b)
|
0/61 | tlexander 2022-06-10 | -- |
65 |
|
● Bluebird的高票通过,竟然只有这么一点涟漪 (196b)
|
0/105 | tlexander 2022-06-10 | -- |
66 |
|
● 2018年的CAR-T、2020年的Tigit、2021年的双抗和PD-1 (27b)
|
0/72 | tlexander 2022-06-10 | -- |
67 |
|
● 为期2天的retreat一般是什么流程? (30b)
|
0/87 | tlexander 2022-06-10 | -- |
68 |
|
● offer咨询 (325b)
|
2/504 | BigPang123 2022-06-09 | BigPang123 06-09 16:36 |
69 |
|
● 报个senior scientist offer (235b)
|
12/2944 | qqattest 2022-06-02 | ducan21 06-06 10:06 |
70 |
|
● 请教大家一下GSK的online job simulation, powered b (143b)
|
1/168 | liufanghe 2022-06-02 | liufanghe 06-06 08:59 |
71 |
|
● droplet digital PCR (ddPCR) 现在成本怎么样? (113b)
|
0/73 | tlexander 2022-06-05 | -- |
72 |
|
● Johnson & Johnson 内推及招人 (611b)
|
2/794 | Fractal 2022-05-24 | Fractal 06-05 03:32 |
73 |
|
● Amylyx会不会成为ALS药的黑马? (246b)
|
1/284 | kingsmen 2022-06-04 | tlexander 06-04 10:50 |
74 |
|
● AAV pk LNP,LNP的免疫原型和毒性如何? (592b)
|
0/130 | tlexander 2022-06-03 | -- |
75 |
|
● 现在做pooled safety analysis (PDF)&# (70b)
|
0/46 | tlexander 2022-06-03 | -- |
76 |
|
● AAV在体内的PK大概是如何的 不同血清型是否差别很大? (51b)
|
0/68 | tlexander 2022-06-02 | -- |
77 |
|
● 好像针对各种基因融合的晚期实体瘤的疗法成功率蛮高 (84b)
|
0/61 | tlexander 2022-06-02 | -- |
78 |
|
● 甲骨文买Cerner是出于什么目的?TDOC还吃香吗? (45b)
|
0/34 | tlexander 2022-06-01 | -- |
79 |
|
● PROTAC, LYTAC, AUTAC, ATTEC, RIBOTAC (15b)
|
1/98 | tlexander 2022-05-31 | tlexander 06-01 23:51 |
80 |
|
● 新公司Stock option (280b)
|
2/741 | macrophage1 2022-06-01 | uknowiknow 06-01 22:26 |
81 |
|
● BioMarin在业界到底什么地位?? (32b)
|
1/264 | tlexander 2022-05-31 | Tevez10 06-01 15:06 |
82 |
|
● HEK293的代表作品是luxtirna和zolgensma; bac/Sf9的 (290b)
|
0/145 | tlexander 2022-05-31 | -- |
83 |
|
● non-clinical saftey这个部门一般放在哪个department (56b)
|
0/49 | tlexander 2022-05-31 | -- |
84 |
|
● Pre-Clinical和Non-clinical区别?? (124b)
|
3/155 | tlexander 2022-05-31 | tlexander 05-31 18:51 |
85 |
|
● 分享一个公开的New Drug Applications (INDs)的exam (96b)
|
0/131 | tlexander 2022-05-31 | -- |
86 |
|
● 有人下周去ASMS吗? (43b)
|
0/70 | tlexander 2022-05-31 | -- |
87 |
|
● 问一个问题:对于allo cell therapy,FDA要求检测hhv (57b)
|
1/49 | tlexander 2022-05-31 | tlexander 05-31 16:16 |
88 |
|
● 求一个Pfizer的内推 (331b)
|
1/183 | MJ1992 2022-05-30 | ndpan 05-31 14:20 |
89 |
|
● BMS的Ke Xu 和 Boehringer Ingelheim的Yirong Wang (156b)
|
0/369 | tlexander 2022-05-30 | -- |
90 |
|
● IOVA的Autologous Tumor Infiltrating Lymphocytes ( (273b)
|
6/206 | tlexander 2022-05-27 | graceman 05-30 00:36 |
91 |
|
● ICI response的biomarker现在到底有没有公认的比较好 (54b)
|
0/50 | tlexander 2022-05-28 | -- |
92 |
|
● FDA关于MTD and RP2D in oncology的规定 (500b)
|
0/151 | tlexander 2022-05-28 | -- |
93 |
|
● 发个马里兰阿斯利康工作广告,如果违规请告知 (转载) (302b)
|
0/253 | zdchen 2022-05-28 | -- |
94 |
|
● 如何去做:Significant exposure to relevant regula (111b)
|
0/48 | tlexander 2022-05-28 | -- |
95 |
|
● 如何理解biomarker strategy in preclinical discove (115b)
|
0/78 | tlexander 2022-05-28 | -- |
96 |
|
● Mirati的KRAS(G12C) 有点遗憾,暴跌了 (1.5k)
|
2/554 | tlexander 2022-05-27 | trystone 05-27 22:08 |
97 |
|
● 动物模型有两种,一种是疾病模型确定MOA,一种是用来 (319b)
|
3/184 | tlexander 2022-05-27 | tlexander 05-27 18:12 |
98 |
|
● 有些靶点就是天生难对付,两个例子可以说明制药业有 (423b)
|
0/134 | tlexander 2022-05-27 | -- |
99 |
|
● 靶向TP53的药出来后能否获得诺贝尔奖?? (39b)
|
0/81 | tlexander 2022-05-27 | -- |
100 |
|
● 急问几个modified live virus做疫苗的问题! (273b)
|
0/35 | mozhe 2022-05-27 | -- |